A prepro-orexin gene polymorphism is associated with narcolepsy
M. Gencik, MD;,
N. Dahmen, MD;,
S. Wieczorek, Cand. med.,
M. Kasten, Cand. med.,
J. Bierbrauer, MD,
I. Anghelescu, MD,
A. Szegedi, MD,
A. M. Menezes Saecker and
J. T. Epplen, MD
From the Department of Molecular Human Genetics (Drs. Gencik and Epplen, S. Wieczorek and A.M. Menezes Saecker) and Neurologische Klinik (Dr. Bierbrauer), St. Josef-Hospital, Ruhr-University, Bochum; and Psytchiatrische Klinik der Johannes-Gutenberg-Universität Mainz (Drs. Dahmen, Anghelescu, Szegedi, and M. Kasten); Germany.
Address correspondence and reprint requests to Dr. med. Martin Gencik, Molecular Human Genetics, Ruhr-University, D-44780 Bochum, Germany; e-mail: martin.gencik{at}ruhr-uni-bochum.de
The orexin (hypocretin) neurotransmitter system was recentlyshown to be directly involved in the pathogenesis of narcolepsyin two animal models. Furthermore, decreased levels of orexinA in the CSF were shown in narcoleptic patients. To define anygenetic contribution of orexin to the etiology of narcolepsy,the authors screened the entire prepro-orexin gene for mutationsor polymorphisms in 133 patients suffering from narcolepsy.They report an association of a rare polymorphism in the prepro-orexingene with narcolepsy in a cohort of 178 patients.
Narcolepsy is a debilitating disorder of the sleep/wake regulationcharacterized by excessive daytime sleepiness, short episodesof involuntary muscle relaxation (cataplexy), sleep paralysis,and hypnagogue and hypnopompic hallucinations. The etiopathogenesisof narcolepsy has remained unclear despite a strong human leukocyteantigen (HLA) association. Although the HLA-DR2 and the linkedHLA-DQB1*0602 allele isfound in >95% of narcoleptic patientsbut only in 8 to 35% of normal populations,1 the pathogeneticrole of the HLA system has remained unclear, especially becauseautoimmune phenomena are not obvious. Recently, abnormalitiesin the orexin neurotransmitter system have been shown to causenarcolepsy-related symptoms in an orexin-knockout mouse model,2as well as in narcoleptic breeds of Doberman pinschers and Labradorretrievers.3 Finally, orexin A was not detected in seven ofnine patients with narcolepsy, indicating disturbed orexin transmission(limit of the assay: 40 pg/mL). All nine healthy controls showedorexin A levels ranging from 250 to 285 pg/mL.4
Orexin A and orexin B are both encoded by the prepro-orexingene on human chromosome 17q2122. The gene consists oftwo exons and one intron. Exon 2 encodes a propeptide from whichthe orexin A and B are cleaved proteolytically.5 To define anycontributions of genetic variations in the prepro-orexin geneto the etiology of narcolepsy, 178 individuals with clinicallyproven narcolepsy and 189 matched healthy individuals were analyzedgenetically for mutations in the prepro-orexin gene.
Patients were recruited from the University Hospital in Mainzand St. Josef Hospital in Bochum, Germany, and fulfilled diagnosticcriteria of the Diagnostic and Statistical Manual of MentalDisorders, 4th edition (DSM IV) and the International Classificationof Sleep Disease of the American Sleep Disorders Associationfor narcolepsy. All but three patients reported cataplecticattacks. In these three patients, the diagnosis was establishedby multiple sleep latency tests (MSLT) and polysomnographicfindings in addition to the presence of other REM-associatedclinical symptoms. All diagnoses were checked by an experiencedphysician (N.D.). Most narcoleptic patients visited our departmentto participate in a narcolepsy research program or were visitedby a member of the research team at home. Narcolepsy symptoms,severity of symptoms, and the total duration of various aspectsof the symptomatology were assessed by a semistructured clinicalinterview. The clinical interview included symptom checklistsfor narcolepsy, including MSLT and polysomnography. Patientswho had not undergone these diagnostic procedures were onlyadmitted to the study when unambiguous cataplexies, additionalREM-associated symptoms, and severe daytime sleepiness werereported (n = 13). To exclude symptomatic narcolepsies, medicalhistory was assessed and a neurologic examination was performed.The control group included 189 matched healthy individuals,89 of whom were extensively neurologically investigated. Allparticipants gave written, informed consent. The study designwas approved by the local ethics committee.
A 770-bp region of the prepro-orexin promoter and both exonsand the intron were amplified in five different PCR systems( table). One hundred thirty-three narcoleptic patients werescreened by single-strand conformation polymorphism (SSCP) analysiswith at least two different polyacrylamide gel electrophoreticconditions. PCR products longer than 270 bp were digested withrestriction endonucleases (see the table). Shifted bands wereeluted out of the gel, reamplified, and directly analyzed ona 377ABI automatic sequencer (PE Biosystems). For confirmatorypurposes, the newly detected C3250T polymorphism in the 5' untranslatedregion (UTR) was typed in 45 additional narcoleptic patients.HLA-DR2 typing was performed as described.6 Allele frequenciesof patients with narcolepsy and the control group were compared;significance was calculated by 2-test.
The mutation analysis in the prepro-orexin revealed a sequencevariation C3250T (reference accession number AF118885) in the5' UTR, 22 bp 5' from the start codon. The 3250T allele waspresent in six of 178 narcoleptic patients, as well as in onehealthy control subject out of 189 (p < 0.05, OR = 6.5).
Furthermore, an insertion of a single nucleotide A at position2679 (reference sequence accession number AF118885) in a singlepatient was detected. This variation is situated in a tractof seven consecutive adenine residues in the promoter region.The functional relevance is not yet clear. No other polymorphismscould be detected in the investigated region of more than 2kb of the prepro-orexin gene.
To define the HLA-DR2 status in 3250T+ patients, HLA-DR typingwas performed. All six patients were HLA-DR2+. These resultsare in agreement with the described HLA-DR distribution in narcolepticpatients. The only healthy individual carrying the 3250T allelewas typed as HLA-DR2 negative.
The data described above provide a suggestive evidence for adirect involvement of the prepro-orexin gene in the etiologyof human narcolepsy. Yet, there are major differences betweenthe animal models and the human association demonstrated. Firstly,human narcolepsy appears to be transmitted in most cases asa multifactorial trait, implying that the 3250T allele predisposestogether with other genetic or environmental factors. Conversely,mutations in genes of the orexin system are causative in theaforementioned animal models. Whether the effects of the 3250Tallele and the DR2/DQB1*0602 haplotype act synergistically isnot yet known. The coexistence of the 3250T allele and HLA-DR2in all six indicates an independent etiologic contribution.Furthermore, the effect of the 3250T allele influences onlya small proportion of patients with narcolepsy (3%), supportingthe concept of genetic heterogeneity. We need to clarify whetherthere are any 3250T+ healthy individuals who harbor the DR2/DQB1*0602haplotype.
Peyron et al.7 described a 18-year-old man who is carrier ofa leucine-to-arginine mutation in the signaling sequence ofthe orexin peptide. This patient was characterized by a veryearly onset of symptoms (cataplexies since the age of 6 months)and a particularly severe course of the narcolepsy, in additionto the presence of periodic leg movements and bulimia. Thisobservation highlights the possibility of a genetic heterogeneityin narcolepsy, and prompted us to closely examine the symptomatologyof our 3250T+ patients. However, no outstanding clinical featuresamong 3250T+ patients were observed. The age at onset of symptomswas 7, 15, 15, 30, 32, and 36 years. All patients exhibitedcataplexies, sleep attacks, automatic behavior, and sleep paralysis.Four of the six patients had hypnagogic hallucinations.
Finally, the traits in the orexin-knockout mouse and the narcolepticdog breeds are both inherited in an autosomal recessive manner.In contrast, all 3250T+ patients were typed heterozygous, suggestingdominant influence. It is conceivable that the 3250T alleleacts directly or via linked sequence variants to influence theexpression of orexin negatively by diminished transcriptionalactivity or decreased RNA stability. However, the functionalrelevance has not been addressed directly in this study andremains to be established by independent means.
Acknowledgments
Supported by FoRUMF 179/99.
Footnotes
J.B. is currently affiliated with Klinik für Psychiatrieund Psychotherapie II der Johann Wolfgang Goethe-Universität,Frankfurt, Germany.
Mignot E, Hayduk R, Black J, Grumet FC, Guilleminault C. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997; 20: 10121020.[Medline]
Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999; 98: 437451.[Medline]
Lin L, Faraco J, Li R, Kadotani H, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999; 98: 365376.[Medline]
Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000; 355: 3940.[Medline]
Sakurai T, Moriguchi T, Furuya K, et al. Structure and function of human prepro-orexin gene. J Biol Chem 1999; 74: 1777117776.
Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225235.[Medline]
Peyron C, Faraco J, Rogers et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; 6: 991997.[Medline]
Received April 13, 2000.
Accepted in final form October 5, 2000.
This article has been cited by other articles:
C. T. Beuckmann, C. M. Sinton, S. C. Williams, J. A. Richardson, R. E. Hammer, T. Sakurai, and M. Yanagisawa Expression of a Poly-Glutamine-Ataxin-3 Transgene in Orexin Neurons Induces Narcolepsy-Cataplexy in the Rat
J. Neurosci.,
May 5, 2004;
24(18):
4469 - 4477.
[Abstract][Full Text][PDF]
J. P. Kukkonen, T. Holmqvist, S. Ammoun, and K. E. O. Akerman Functions of the orexinergic/hypocretinergic system
Am J Physiol Cell Physiol,
December 1, 2002;
283(6):
C1567 - C1591.
[Abstract][Full Text][PDF]
M. Hungs, L. Lin, M. Okun, and E. Mignot Polymorphisms in the vicinity of the hypocretin/orexin are not associated with human narcolepsy
Neurology,
November 27, 2001;
57(10):
1893 - 1895.
[Abstract][Full Text][PDF]
B. R. Olafsdottir, D. B. Rye, T. E. Scammell, J. K. Matheson, K. Stefansson, and J. R. Gulcher Polymorphisms in hypocretin/orexin pathway genes and narcolepsy
Neurology,
November 27, 2001;
57(10):
1896 - 1899.
[Abstract][Full Text][PDF]
M. H. Silber and D. B. Rye Solving the mysteries of narcolepsy: The hypocretin story
Neurology,
June 26, 2001;
56(12):
1616 - 1618.
[Full Text][PDF]
M. A. Dalal, A. Schuld, M. Haack, M. Uhr, P. Geisler, I. Eisensehr, S. Noachtar, and T. Pollmacher Normal plasma levels of orexin A (hypocretin-1) in narcoleptic patients
Neurology,
June 26, 2001;
56(12):
1749 - 1751.
[Abstract][Full Text][PDF]